Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
TUCSON, Ariz., March 21, 2017 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents, and services for molecular profiling applications, today announced that the Company will release 2016 fourth quarter and full year financial results after market close on Thursday, March 23, 2017. Company management will host an investment-community conference call beginning at 5:00pm Eastern Time on Thursday, March 23 to discuss these results and answer questions.
Individuals interested in listening to the conference call may do so by dialing (866) 394-4225 for domestic callers, or (678) 509-7535 for international callers (conference ID: 91525538), or from the webcast on the “Investors” section of the Company’s website at: www.htgmolecular.com. The webcast will be available on the Company’s website for 90 days following the completion of the call.
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013, the company commercialized its first instrument platform and a portfolio of RNA assays that leveraged HTG's original proprietary nuclease protection chemistry. Continuous improvement led to the 2014 launch of the company’s HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
